Doç. Dr. Yaşa Gül Mutlu

Balik Aydin B, Mutlu YG, Sevindik OG. Persistent Polyclonal B-Cell Lymphocytosis with Binucleated Lymphocytes. Turk J Haematol. 2021;38(2):173-4.

Kaynak: florence.com.tr profil sayfası

Civriz Bozdag S, Cengiz Seval G, Yonal Hindilerden I, Hindilerden F, Andic N, Baydar M, …. Mutlu YG ,…et al. Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies. Turk J Haematol. 2022;39(1):43- 54.

Kaynak: florence.com.tr profil sayfası

Sevindik OG, Mergen M, Mergen S, Mutlu YG, Aydin BB, Serin I. To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission. Ann Hematol. 2022;101(11):2545-7.

Kaynak: florence.com.tr profil sayfası

Sevindik OG, Mutlu YG, Aydin BB, Serin I. First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS). Hemasphere. 2022;6(7):e728.

Kaynak: florence.com.tr profil sayfası

Yigit Kaya S, Bektas S, Askin AE, Balik Aydin B, Mutlu YG, Sevindik OG. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient. Ann Hematol. 2023;102(6):1599-600.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Aydin BB, Erdogan C, Kizilaslan D, Bekoz HS, Gemici A, et al. Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation: Intensive Care Outcome in Hematopoietic Stem Cell Transplantation. Indian J Hematol Blood Transfus. 2023;39(2):167-72.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Balik Aydin B, Ayaz A, Seca F, Sevindik OG. Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing andclinical implications. Annals of Medical Research. 2022; 29(4), 406-411.

Kaynak: florence.com.tr profil sayfası

Sadri S. , Yönal Hindilerden İ. , Mutlu YG. , Tiryaki T. O. , Gemici A. İ. , Bekoz H. S. , Gökmen Sevindik Ö. , Hindilerden F. , Kalayoğlu beşışık S. , Nalçacı M. , Sargın D. Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers. Eur Res J. 2023; 1-12.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Aydin BB, Cakir A, Canoz O, Erol C, Sevindik OG.Should core needle lymph node biopsy be a relevant alternative to surgical excisional biopsy in diagnostic work up of lymphomas? 2023, Eurasian J Med.

Kaynak: florence.com.tr profil sayfası

Erol VB, Mutlu YG, Aydin BB, Mert A, Sevindik OG. Intravascular B cell lymphoma with generalized telangiectasias: a rare entity. 2023, J Dtsch Dermatol Ges.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Sevcik J, Kiss JE, Lister J, Moore LR, Donnenberg AD. Predicting the CD34 content of mobilized peripheral blood leukapheresis products: single institution experience over 20 years. Cytotherapy. 2023.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Yigit Kaya S, Maral S, Melek E, Baslar Z, Kaynar L, et al. Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. Front Immunol. 2023;14:1276295.

Kaynak: florence.com.tr profil sayfası

Serin I, Sevindik OG, Balik Aydin B, Melek E, Mutlu YG, Bilgen H, et al. Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics? Transfus Apher Sci. 2023;62(6):103809.

Kaynak: florence.com.tr profil sayfası

Askin AE, Bektas S, Serin I, Mutlu YG, Aydin BB, Sevindik OG. Germline CEBPA Mutation as a Rare Cause of Chronic Neutropenia. Indian J Hematol Blood Transfus. 2024;40(3):527-30.

Kaynak: florence.com.tr profil sayfası

Sevindik OG, Mutlu YG, Demirkan F. The Contributions of Turkish Hematology to the Global Literature: A Comparative Analysis. Turk J Haematol. 2025;42(3):246-9. doi:10.4274/tjh.galenos.2025.2025.0029.

Kaynak: florence.com.tr profil sayfası

Yigit Kaya S, Kaynar L, Mutlu YG, Yildirim M, Serin I, Avci DN et al. Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience. Transpl Immunol. 2025;93:102286. doi:10.1016/j.trim.2025.102286

Kaynak: florence.com.tr profil sayfası

Yigit Kaya S, Melek E, Mutlu YG, Bekoz HS, Maral S, Kaynar L et al. When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma. Ann Hematol. 2025;104(3):2079-80. doi:10.1007/s00277-025-06285-2.

Kaynak: florence.com.tr profil sayfası

Yigit Kaya S, Mutlu YG, Malkan UY, Mehtap O, Keklik Karadag F, Korkmaz G et al. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience. Leuk Res. 2024;140:107495. doi:10.1016/j.leukres.2024.107495

Kaynak: florence.com.tr profil sayfası

Yigit Kaya S, Mutlu YG, Yucel OK, Nizam Ozen I, Atas U, Melek E et al. Original vs. Generic Plerixafor for the Mobilization of Stem Cells in Multiple Myeloma Patients. Indian J Hematol Blood Transfus. 2025;41(1):38-42. doi:10.1007/s12288-024-01841-8.

Kaynak: florence.com.tr profil sayfası

Mutlu YG, Emre Unsal S, Gulec B, Serin I, Arslan Davulcu E, Sonmez GM et al. The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History. Clin Lymphoma Myeloma Leuk. 2025. doi:10.1016/j.clml.2025.10.006.

Kaynak: florence.com.tr profil sayfası

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM et al. Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients. Am J Hematol. 2026;101(1):89-96. doi:10.1002/ajh.70142.

Kaynak: florence.com.tr profil sayfası